OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Veracyte will present Phase III data from the OPTIMA and ENZAMET trials at the 2026 ASCO Annual Meeting, providing new evidence for its Prosigna and Decipher Prostate tests. The OPTIMA study, involving over 4,400 patients, demonstrates how Prosigna can guide chemotherapy decisions in high-risk early-stage breast cancer, offering Level 1A evidence. The ENZAMET study data shows how Decipher Prostate can help metastatic prostate cancer patients avoid unnecessary treatment by predicting benefit from docetaxel intensification.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.